+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Equity in Access Research Grants

Leukemia & Lymphoma Society’s (LLS)

The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors.

Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care. Learn about our 2024 Equity in Access Research Program grantees and their research following this year’s application information.

AI Based Application Success Predictor

1. Established Investigator Track & Independence

The Discovery Grant Program requires principal investigators to have ≥3 years of independent faculty experience, with strong preliminary data and proof-of-concept to explore novel biological mechanisms or biomarkers .

🚀 2. Innovation in Blood Cancer Biology

Projects should focus on mechanisms like clonal evolution, resistance, tumor–microenvironment interactions, neoantigen discovery, or novel detection tools—aiming for transformative ideas, not confirmatory studies.

🧠 3. Translational & Community‑Focused Initiatives

Programs such as IMPACT and Equity in Access support trials that improve clinical access to underrepresented patients, often via hub-and-spoke models connecting academic centers with community sites.

These initiatives emphasize health-services research to break down barriers to trial participation .

🤝 4. Strategic Alignment with LLS Equity and Immunotherapy Priorities

LLS is heavily invested—$28M+ this year alone—in immunotherapeutic strategies (e.g., CAR-T, bispecifics, immune checkpoint inhibitors).

Equity-focused grants target interventions that increase clinical trial access among racially and socioeconomically underserved groups .

💵 5. Appropriate Budgeting & Feasible Timelines

Discovery Grants allow up to $250K/year (max $750K total), including ≤10% indirect costs 

IMPACT grants offer up to $250K/year (plus an optional $150K/year) over 5 years, prioritizing network-building and sustainability .

🧭 6. Two‑Stage Review with Clear Calls & LOIs

Many programs (Discovery, Equity, IMPACT) use Letter of Intent (LOI) followed by invitation to full application.

Applicants must follow explicit scope guidelines, timelines, and objectives .

📊 7. Evidence of Impact from Prior LLS Support

LLS-funded research has led to FDA-approved treatments (~85% of approvals since 2017) and major trials like Beat AML—demonstrating real-world impact and accelerating survival outcomes.

✅ 🧩 Summary Table

Success Factor	What It Means
PI independence & track record	≥3 years faculty; data-driven hypothesis
High novelty & impact	Novel mechanisms, biomarkers, technologies
Translational/community focus	Hub‑community models; health equity emphasis
Priority alignment	Immunotherapy or access-equity alignment
Budget & feasibility	Adheres to cost limits and timeline realism
Structured LOI process	Early adherence to call scope and deadlines
Prior measurable impact	Evidence of research translating into patient benefit

🧠 Final Takeaway

To enhance your competitiveness for LLS funding:

Demonstrate scientific novelty with solid early data and independent PI credentials.

Tailor your proposal to LLS’s specialized programs—Discovery for novel biology; Equity/IMPACT for clinical access.

Adhere strictly to budget, timing, and LOI requirements.

Highlight translational outcomes or patient‑centered impact, leveraging LLS’s track record of turning funded research into real-world gains.

Specialties

Cancer

Neurosciences

Eligibility Requirements

The application will require a Principal Investigator who is responsible for proposal submission and conduct of the study, including adherence to all stipulations made by LLS in this document, and in the Funding Agreement, if funded. Study teams may also include one or two Co-Principal Investigator(s) and multiple Co-Investigators. Study teams must also include at least one stakeholder (e.g., community oncologists, patients, clinical research staff, patient navigators).

LLS welcomes Principal Investigators at all stages of their careers, as well as Principal Investigators who have not previously conducted research in the area of blood cancer. However, if the Principal Investigator is an early career investigator, a more experienced Co-Principal Investigator is required. Principal Investigator(s) must meet the following eligibility criteria:

• The Principal Investigator must be affiliated with a public or nonprofit institution
(tax exempt under Section 501(c)(3) of the Internal Revenue Code).
• The sponsoring institution must be based in the United States or its territories.
• The Principal Investigator must have a PhD, MD, DO, ScD, JD, or equivalent
doctoral degree

The Principal Investigator and other study team members may come from a variety of disciplines, including but not limited to medicine/oncology, nursing, social work, public health, health services research, economics, sociology, health communication, epidemiology, and biostatistics. We strongly encourage multi-disciplinary teams.

Consistent with LLS’s commitment to diversity, equity, and inclusion, we encourage applications that have investigators and/or research team members from backgrounds historically underrepresented in research disciplines as a result of their race, ethnicity, socioeconomic status, disability, or other factors.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Leukemia & Lymphoma Society’s (LLS)

Sponsor Type: Corporate/Non-Profit

Address: 1201 15th Street N.W., Suite 410 Washington, D.C. 20005 (888) 557-7177

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity